ProCE Banner Activity

HPTN 084: Long-Acting Injectable Cabotegravir Superior to Daily Oral TDF/FTC for HIV PrEP in Cisgender Women

Slideset Download
Conference Coverage
Monthly cabotegravir injections were associated with an 89% lower risk of HIV infection vs daily oral TDF/FTC; both strategies were generally safe and well tolerated, with no discontinuations for injection-site reactions.

Released: January 30, 2021

Expiration: January 29, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2021 HIV R4P

ProCE Banner